ABBOTT LABORATORIES Cash and Cash Equivalents, Period Increase (Decrease)
ABBOTT LABORATORIES (ABT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$9.21 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-16
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$1.60B, a 109.96% decline year-over-year.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $1.34B.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $969.00M.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$9.91B.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$9.21B, a 167.65% decline from fiscal 2016.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for fiscal 2016 was $13.62B, a 1351.92% increase from fiscal 2015.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for fiscal 2015 was $938.00M, a 59.52% increase from fiscal 2014.
- ABBOTT LABORATORIES cash and cash equivalents, period increase (decrease) for fiscal 2014 was $588.00M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$1.60B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$268.00M derived: sum of 2 quarters · filed 2018-02-16 | $701.00M derived: sum of 3 quarters · filed 2018-02-16 | -$9.21B 10-K · filed 2018-02-16 | ||||
| 2017-09-30 | $1.34B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $2.31B derived: sum of 2 quarters · filed 2017-11-02 | -$7.61B 10-Q · filed 2017-11-02 | $8.51B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2017-06-30 | $969.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$8.95B 10-Q · filed 2017-08-02 | $7.17B derived: sum of 3 quarters · filed 2018-02-16 | $7.10B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2017-03-31 | -$9.91B 10-Q · filed 2017-05-03 | $6.21B derived: sum of 2 quarters · filed 2018-02-16 | $6.13B derived: sum of 3 quarters · filed 2018-02-16 | $5.37B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-12-31 | $16.12B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $16.04B derived: sum of 2 quarters · filed 2018-02-16 | $15.29B derived: sum of 3 quarters · filed 2018-02-16 | $13.62B 10-K · filed 2018-02-16 | ||||
| 2016-09-30 | -$78.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$834.00M derived: sum of 2 quarters · filed 2017-11-02 | -$2.50B 10-Q · filed 2017-11-02 | -$632.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | -$756.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$2.42B 10-Q · filed 2017-08-02 | -$554.00M derived: sum of 3 quarters · filed 2018-02-16 | -$1.47B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | -$1.67B 10-Q · filed 2017-05-03 | $202.00M derived: sum of 2 quarters · filed 2018-02-16 | -$714.00M derived: sum of 3 quarters · filed 2018-02-16 | $108.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $1.87B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $953.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.77B derived: sum of 3 quarters · filed 2018-02-16 | $938.00M 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | -$916.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$94.00M derived: sum of 2 quarters · filed 2016-11-03 | -$931.00M 10-Q · filed 2016-11-03 | -$481.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $822.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$15.00M 10-Q · filed 2016-08-03 | $435.00M derived: sum of 3 quarters · filed 2017-02-17 | $478.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | -$837.00M 10-Q · filed 2016-05-04 | -$387.00M derived: sum of 2 quarters · filed 2017-02-17 | -$344.00M derived: sum of 3 quarters · filed 2017-02-17 | $1.17B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $450.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $493.00M derived: sum of 2 quarters · filed 2017-02-17 | $2.00B derived: sum of 3 quarters · filed 2017-02-17 | $588.00M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.55B derived: sum of 2 quarters · filed 2015-11-05 | $138.00M 10-Q · filed 2015-11-05 | $731.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $1.51B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $95.00M 10-Q · filed 2015-08-04 | $688.00M derived: sum of 3 quarters · filed 2016-02-19 | -$2.00B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | -$1.42B 10-Q · filed 2015-05-06 | -$822.00M derived: sum of 2 quarters · filed 2016-02-19 | -$3.51B derived: sum of 3 quarters · filed 2016-02-19 | -$2.31B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | $593.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$2.10B derived: sum of 2 quarters · filed 2016-02-19 | -$898.00M derived: sum of 3 quarters · filed 2016-02-19 | -$7.33B 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | -$2.69B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$1.49B derived: sum of 2 quarters · filed 2014-11-06 | -$7.92B 10-Q · filed 2014-11-06 | -$7.92B 10-Q · filed 2013-11-07 | -$5.12B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-06-30 | $1.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$5.23B 10-Q · filed 2014-08-05 | -$5.23B 10-Q · filed 2013-08-06 | -$2.43B derived: sum of 3 quarters · filed 2015-02-27 | -$1.48B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-03-31 | -$6.43B 10-Q · filed 2014-05-07 | -$6.43B 10-Q · filed 2013-05-08 | -$3.62B derived: sum of 2 quarters · filed 2015-02-27 | -$2.68B derived: sum of 3 quarters · filed 2015-02-27 | $26.91M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $2.80B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $3.75B derived: sum of 2 quarters · filed 2015-02-27 | $6.46B derived: sum of 3 quarters · filed 2015-02-27 | $3.99B 10-K · filed 2015-02-27 | ||||
| 2012-09-30 | $944.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $3.65B derived: sum of 2 quarters · filed 2013-11-07 | $1.18B 10-Q · filed 2013-11-07 | $2.95B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2012-06-30 | $2.71B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $239.96M 10-Q · filed 2013-08-06 | $2.00B derived: sum of 3 quarters · filed 2014-02-21 | $2.98B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2012-03-31 | -$2.47B 10-Q · filed 2013-05-08 | -$702.84M derived: sum of 2 quarters · filed 2014-02-21 | $269.44M derived: sum of 3 quarters · filed 2014-02-21 | $1.61B derived: sum of 4 quarters · filed 2014-02-21 | ||||
| 2011-12-31 | $1.76B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $2.74B derived: sum of 2 quarters · filed 2014-02-21 | $4.07B derived: sum of 3 quarters · filed 2014-02-21 | $3.17B 10-K · filed 2014-02-21 | $3.16B 10-K · filed 2012-02-21 | |||
| 2011-09-30 | $972.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.31B derived: sum of 2 quarters · filed 2012-11-07 | $1.40B 10-Q · filed 2012-11-07 | $1.23B derived: sum of 4 quarters · filed 2012-11-07 | ||||
| 2011-06-30 | $1.34B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $428.65M 10-Q · filed 2012-08-07 | $258.87M derived: sum of 3 quarters · filed 2012-08-07 | -$244.68M derived: sum of 4 quarters · filed 2012-08-07 | ||||
| 2011-03-31 | -$908.22M 10-Q · filed 2012-05-08 | -$1.08B derived: sum of 2 quarters · filed 2012-05-08 | -$1.58B derived: sum of 3 quarters · filed 2012-05-08 | $1.17B derived: sum of 4 quarters · filed 2012-05-08 | ||||
| 2010-12-31 | -$169.77M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | -$673.33M derived: sum of 2 quarters · filed 2012-02-21 | $2.08B derived: sum of 3 quarters · filed 2012-02-21 | -$5.16B 10-K · filed 2012-02-21 | ||||
| 2010-09-30 | -$503.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $2.25B derived: sum of 2 quarters · filed 2011-11-04 | -$4.99B 10-Q · filed 2011-11-04 | -$1.06B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $2.75B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-04 | -$4.49B 10-Q · filed 2011-08-04 | -$554.21M derived: sum of 3 quarters · filed 2012-02-21 | $117.40M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | -$7.24B 10-Q · filed 2011-05-06 | -$3.31B derived: sum of 2 quarters · filed 2012-02-21 | -$2.64B derived: sum of 3 quarters · filed 2012-02-21 | -$3.31B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $3.93B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $4.61B derived: sum of 2 quarters · filed 2012-02-21 | $3.93B derived: sum of 3 quarters · filed 2012-02-21 | $4.70B 10-K · filed 2012-02-21 | ||||
| 2009-09-30 | $671.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $1.12M derived: sum of 2 quarters · filed 2010-11-05 | $763.89M 10-Q · filed 2010-11-05 | $2.07B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-06-30 | -$670.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-05 | $92.28M 10-Q · filed 2010-08-05 | $1.39B derived: sum of 3 quarters · filed 2011-02-18 | $407.72M derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-03-31 | $762.77M 10-Q · filed 2010-05-04 | $2.06B derived: sum of 2 quarters · filed 2011-02-18 | $1.08B derived: sum of 3 quarters · filed 2011-02-18 | |||||
| 2008-12-31 | $1.30B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $315.44M derived: sum of 2 quarters · filed 2011-02-18 | $1.66B 10-K · filed 2011-02-18 | |||||
| 2008-09-30 | -$986.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | $353.96M 10-Q · filed 2009-11-06 | ||||||
| 2008-06-30 | $1.34B 10-Q · filed 2009-08-07 | |||||||
| 2007-12-31 | $1.94B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |